Cepheid Announces Accelerated Development of Flu A Panel Test
SUNNYVALE, Calif., Sept. 9 /PRNewswire-FirstCall/ — Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types. Following review of the Request for Consideration for Emergency Use Authorization (EUA) by the U.S. Food & Drug Administration (FDA), the test is expected to be authorized for use during the upcoming influenza season, with product shipments beginning in January 2010.
“In reviewing the needs of the healthcare system, it became apparent that the GeneXpert is a key potential solution to the universal need for rapid and accurate flu testing on both a centralized and disseminated basis,” said John Bishop, Cepheid’s Chief Executive Officer. “In recognition of this universal need, we reprioritized longer term projects within the company in order to deliver this product in a timely manner.”
Subsequent to the EUA request for consideration by the FDA, the test will be made available in Europe as a CE IVD product.
“Currently, laboratories do not have a rapid test to discriminate among the multiple influenza strains expected to be present this flu season — each of which have different antiviral drug susceptibilities,” said David Persing, MD, PhD, Cepheid’s Executive Vice President, Chief Medical & Technology Officer. “To make this test available as quickly as possible, we plan to accelerate development by leveraging the work completed on a previous influenza project supported through a 2007 contract with the Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC).”
Following EUA request to the FDA, development of Cepheid’s Flu Panel test will continue by adding additional target identification for Flu B. For that product, a separate 510(k) submission is expected in 2010.
About the GeneXpert System
The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market. See www.cepheid.com for more information.
This press release contains forward-looking statements that are not purely historical regarding Cepheid’s or its management’s intentions, beliefs, expectations and strategies for the future, including those relating to the timing of new product releases, the timing and likelihood of regulatory review and approval, product performance, and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company’s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen product development and manufacturing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing; customer and market acceptance of the product; the failure of the product to perform as expected, whether due to manufacturing errors, design defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the product; and underlying market conditions worldwide. Readers should also refer to the section entitled “Risk Factors” in Cepheid’s Annual Report on Form 10-K for 2008 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
CONTACTS: For Media Inquiries: For Cepheid Investor Inquiries: Jared Tipton Jacquie Ross Cepheid Corporate Communications Cepheid Investor Relations 408-400-8377 408-400-8329 email@example.com firstname.lastname@example.org